{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:02:41Z","timestamp":1794852161182,"version":"4.9.1"},"reference-count":200,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1038\/s41582-024-00999-z","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T15:10:42Z","timestamp":1722957042000},"page":"526-540","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Gaucher disease provides a unique window into Parkinson disease pathogenesis"],"prefix":"10.1038","volume":"20","author":[{"given":"Ellen","family":"Hertz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Sidransky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"key":"999_CR1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1001\/jamaneurol.2013.1925","volume":"70","author":"MA Nalls","year":"2013","unstructured":"Nalls, M. A. et al. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol. 70, 727\u2013735 (2013).","journal-title":"JAMA Neurol."},{"key":"999_CR2","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky, E. et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease. N. Engl. J. Med. 361, 1651\u20131661 (2009).","journal-title":"N. Engl. J. Med."},{"key":"999_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe, W. et al. Parkinson disease. Nat. Rev. Dis. Prim. 3, 17013 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"999_CR4","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","volume":"18","author":"MA Nalls","year":"2019","unstructured":"Nalls, M. A. et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson\u2019s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 18, 1091\u20131102 (2019).","journal-title":"Lancet Neurol."},{"key":"999_CR5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/S1096-7192(03)00071-4","volume":"79","author":"N Tayebi","year":"2003","unstructured":"Tayebi, N. et al. Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol. Genet. Metab. 79, 104\u2013109 (2003).","journal-title":"Mol. Genet. Metab."},{"key":"999_CR6","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/qjmed\/89.9.691","volume":"89","author":"O Neudorfer","year":"1996","unstructured":"Neudorfer, O. et al. Occurrence of Parkinson\u2019s syndrome in type I Gaucher disease. QJM 89, 691\u2013694 (1996).","journal-title":"QJM"},{"key":"999_CR7","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1136\/jmg.2004.024455","volume":"41","author":"O Goker-Alpan","year":"2004","unstructured":"Goker-Alpan, O. et al. Parkinsonism among Gaucher disease carriers. J. Med. Genet. 41, 937\u2013940 (2004).","journal-title":"J. Med. Genet."},{"key":"999_CR8","doi-asserted-by":"publisher","first-page":"212.e5","DOI":"10.1016\/j.neurobiolaging.2016.04.022","volume":"45","author":"C Ran","year":"2016","unstructured":"Ran, C. et al. Strong association between glucocerebrosidase mutations and Parkinson\u2019s disease in Sweden. Neurobiol. Aging 45, 212.e5\u2013e11 (2016).","journal-title":"Neurobiol. Aging"},{"key":"999_CR9","doi-asserted-by":"publisher","first-page":"267.e7","DOI":"10.1016\/j.neurobiolaging.2018.06.027","volume":"71","author":"AK Emelyanov","year":"2018","unstructured":"Emelyanov, A. K. et al. Mutation analysis of Parkinson\u2019s disease genes in a Russian data set. Neurobiol. Aging 71, 267.e7\u2013 e10 (2018).","journal-title":"Neurobiol. Aging"},{"key":"999_CR10","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/mds.21892","volume":"23","author":"EV De Marco","year":"2008","unstructured":"De Marco, E. V. et al. Glucocerebrosidase gene mutations are associated with Parkinson\u2019s disease in southern Italy. Mov. Disord. 23, 460\u2013463 (2008).","journal-title":"Mov. Disord."},{"key":"999_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/jhg.2014.110","volume":"60","author":"Z Yu","year":"2015","unstructured":"Yu, Z. et al. Mutations in the glucocerebrosidase gene are responsible for Chinese patients with Parkinson\u2019s disease. J. Hum. Genet. 60, 85\u201390 (2015).","journal-title":"J. Hum. Genet."},{"key":"999_CR12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/hmg\/ddq454","volume":"20","author":"S Lesage","year":"2011","unstructured":"Lesage, S. et al. Large-scale screening of the Gaucher\u2019s disease-related glucocerebrosidase gene in Europeans with Parkinson\u2019s disease. Hum. Mol. Genet. 20, 202\u2013210 (2011).","journal-title":"Hum. Mol. Genet."},{"key":"999_CR13","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1001\/archneurol.2007.68","volume":"65","author":"IF Mata","year":"2008","unstructured":"Mata, I. F. et al. Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. Arch. Neurol. 65, 379\u2013382 (2008).","journal-title":"Arch. Neurol."},{"key":"999_CR14","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1093\/brain\/awx285","volume":"140","author":"LA Robak","year":"2017","unstructured":"Robak, L. A. et al. Excessive burden of lysosomal storage disorder gene variants in Parkinson\u2019s disease. Brain 140, 3191\u20133203 (2017).","journal-title":"Brain"},{"key":"999_CR15","unstructured":"Gaucher, P. C. E. De l\u2019Epithelioma Primitif de la Rate: Hypertrophie Idiopathique de la Rate sans Leuc\u00e9mie [French]. Thesis, Facult\u00e9 de Med\u00e9cine de Paris (1882)."},{"key":"999_CR16","unstructured":"Aghion, H. La Maladie de Gaucher dans l\u2019Enfance (Forme Cardio-R\u00e9nale) [French]. Thesis, Facult\u00e9 de M\u00e9decine de Paris (1934)."},{"key":"999_CR17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/0006-291X(65)90743-6","volume":"18","author":"RO Brady","year":"1965","unstructured":"Brady, R. O., Kanfer, J. N. & Shapiro, D. Metabolism of glucocerebrosides II. Evidence of an enzymatic deficiency in Gaucher\u2019s disease. Biochem. Biophys. Res. Commun. 18, 221\u2013225 (1965).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"999_CR18","doi-asserted-by":"publisher","first-page":"17C","DOI":"10.1042\/bj0970017C","volume":"97","author":"A Patrick","year":"1965","unstructured":"Patrick, A. A deficiency of glucocerebrosidase in Gaucher\u2019s disease. Biochem. J. 97, 17C\u201324C (1965).","journal-title":"Biochem. J."},{"key":"999_CR19","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","volume":"324","author":"NW Barton","year":"1991","unstructured":"Barton, N. W. et al. Replacement therapy for inherited enzyme deficiency \u2013 macrophage-targeted glucocerebrosidase for Gaucher\u2019s disease. N. Engl. J. Med. 324, 1464\u20131470 (1991).","journal-title":"N. Engl. J. Med."},{"key":"999_CR20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ymgme.2004.08.015","volume":"83","author":"E Sidransky","year":"2004","unstructured":"Sidransky, E. Gaucher disease: complexity in a \u201csimple\u201d disorder. Mol. Genet. Metab. 83, 6\u201315 (2004).","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"999_CR21","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1002\/jimd.12235","volume":"43","author":"R Schiffmann","year":"2020","unstructured":"Schiffmann, R. et al. The definition of neuronopathic Gaucher disease. J. Inherit. Metab. Dis. 43, 1056\u20131059 (2020).","journal-title":"J. Inherit. Metab. Dis."},{"key":"999_CR22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/01.gim.0000196443.42899.25","volume":"8","author":"A Tylki-Szymanska","year":"2006","unstructured":"Tylki-Szymanska, A., Keddache, M. & Grabowski, G. A. Characterization of neuronopathic Gaucher disease among ethnic Poles. Genet. Med. 8, 8\u201315 (2006).","journal-title":"Genet. Med."},{"key":"999_CR23","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/humu.23611","volume":"39","author":"BA Davidson","year":"2018","unstructured":"Davidson, B. A., Hassan, S., Garcia, E. J., Tayebi, N. & Sidransky, E. Exploring genetic modifiers of Gaucher disease: the next horizon. Hum. Mutat. 39, 1739\u20131751 (2018).","journal-title":"Hum. Mutat."},{"key":"999_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/qjmed\/hch036","volume":"97","author":"RH Lachmann","year":"2004","unstructured":"Lachmann, R. H., Grant, I. R., Halsall, D. & Cox, T. M. Twin pairs showing discordance of phenotype in adult Gaucher\u2019s disease. QJM 97, 199\u2013204 (2004).","journal-title":"QJM"},{"key":"999_CR25","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/mds.27916","volume":"35","author":"G Lopez","year":"2020","unstructured":"Lopez, G. et al. Clinical evaluation of sibling pairs with Gaucher disease discordant for parkinsonism. Mov. Disord. 35, 359\u2013365 (2020).","journal-title":"Mov. Disord."},{"key":"999_CR26","doi-asserted-by":"publisher","first-page":"10975","DOI":"10.1016\/S0021-9258(19)78077-6","volume":"269","author":"S Miao","year":"1994","unstructured":"Miao, S. et al. Identification of Glu340 as the active-site nucleophile in human glucocerebrosidase by use of electrospray tandem mass spectrometry. J. Biol. Chem. 269, 10975\u201310978 (1994).","journal-title":"J. Biol. Chem."},{"key":"999_CR27","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1093\/glycob\/10.11.1217","volume":"10","author":"S Fabrega","year":"2000","unstructured":"Fabrega, S. et al. Human glucocerebrosidase: heterologous expression of active site mutants in murine null cells. Glycobiology 10, 1217\u20131224 (2000).","journal-title":"Glycobiology"},{"key":"999_CR28","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/sj.embor.embor873","volume":"4","author":"H Dvir","year":"2003","unstructured":"Dvir, H. et al. X-ray structure of human acid-\u03b2-glucosidase, the defective enzyme in Gaucher disease. EMBO Rep. 4, 704\u2013709 (2003).","journal-title":"EMBO Rep."},{"key":"999_CR29","doi-asserted-by":"publisher","first-page":"10112","DOI":"10.1016\/S0021-9258(18)90936-1","volume":"259","author":"S Takasaki","year":"1984","unstructured":"Takasaki, S. et al. Structure of the N-asparagine-linked oligosaccharide units of human placental \u03b2-glucocerebrosidase. J. Biol. Chem. 259, 10112\u201310117 (1984).","journal-title":"J. Biol. Chem."},{"key":"999_CR30","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/humu.20676","volume":"29","author":"KS Hruska","year":"2008","unstructured":"Hruska, K. S., LaMarca, M. E., Scott, C. R. & Sidransky, E. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum. Mutat. 29, 567\u2013583 (2008).","journal-title":"Hum. Mutat."},{"key":"999_CR31","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cell.2007.10.018","volume":"131","author":"D Reczek","year":"2007","unstructured":"Reczek, D. et al. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of \u03b2-glucocerebrosidase. Cell 131, 770\u2013783 (2007).","journal-title":"Cell"},{"key":"999_CR32","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3109\/10409239009090616","volume":"25","author":"GA Grabowski","year":"1990","unstructured":"Grabowski, G. A., Gaft, S., Horowitz, M. & Kolodny, E. H. Acid \u03b2-glucosidase: enzymology and molecular biology of Gaucher diseas. Crit. Rev. Biochem. Mol. Biol. 25, 385\u2013414 (1990).","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"999_CR33","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.lab.2004.03.013","volume":"144","author":"E Beutler","year":"2004","unstructured":"Beutler, E., Beutler, L. & West, C. Mutations in the gene encoding cytosolic \u03b2-glucosidase in Gaucher disease. J. Lab. Clin. Med. 144, 65\u201368 (2004).","journal-title":"J. Lab. Clin. Med."},{"key":"999_CR34","doi-asserted-by":"publisher","first-page":"37929","DOI":"10.1074\/jbc.M104290200","volume":"276","author":"H Matern","year":"2001","unstructured":"Matern, H., Boermans, H., Lottspeich, F. & Matern, S. Molecular cloning and expression of human bile acid \u03b2-glucosidase. J. Biol. Chem. 276, 37929\u201337933 (2001).","journal-title":"J. Biol. Chem."},{"key":"999_CR35","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/BF00279398","volume":"64","author":"RA Barneveld","year":"1983","unstructured":"Barneveld, R. A. et al. Assignment of the gene coding for human \u03b2-glucocerebrosidase to the region q21-q31 of chromosome 1 using monoclonal antibodies. Hum. Genet. 64, 227\u2013231 (1983).","journal-title":"Hum. Genet."},{"key":"999_CR36","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1089\/dna.1988.7.107","volume":"7","author":"O Reiner","year":"1988","unstructured":"Reiner, O., Wigderson, M. & Horowitz, M. Structural analysis of the human glucocerebrosidase genes. DNA 7, 107\u2013116 (1988).","journal-title":"DNA"},{"key":"999_CR37","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0888-7543(89)90319-4","volume":"4","author":"M Horowitz","year":"1989","unstructured":"Horowitz, M. et al. The human glucocerebrosidase gene and pseudogene: structure and evolution. Genomics 4, 87\u201396 (1989).","journal-title":"Genomics"},{"key":"999_CR38","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1086\/367850","volume":"72","author":"N Tayebi","year":"2003","unstructured":"Tayebi, N. et al. Reciprocal and nonreciprocal recombination at the glucocerebrosidase gene region: implications for complexity in Gaucher disease. Am. J. Hum. Genet. 72, 519\u2013534 (2003).","journal-title":"Am. J. Hum. Genet."},{"key":"999_CR39","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adk1296","volume":"10","author":"EK Gustavsson","year":"2024","unstructured":"Gustavsson, E. K. et al. The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1. Sci. Adv. 10, eadk1296 (2024).","journal-title":"Sci. Adv."},{"key":"999_CR40","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1056\/NEJM198703053161002","volume":"316","author":"S Tsuji","year":"1987","unstructured":"Tsuji, S. et al. A mutation in the human glucocerebrosidase gene in neuronopathic Gaucher\u2019s disease. N. Engl. J. Med. 316, 570\u2013575 (1987).","journal-title":"N. Engl. J. Med."},{"key":"999_CR41","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1203\/00006450-199805000-00003","volume":"43","author":"N Tayebi","year":"1998","unstructured":"Tayebi, N. et al. Genotypic heterogeneity and phenotypic variation among patients with type 2 Gaucher\u2019s disease. Pediatr. Res. 43, 571\u2013578 (1998).","journal-title":"Pediatr. Res."},{"key":"999_CR42","volume":"2015","author":"E Shemesh","year":"2015","unstructured":"Shemesh, E. et al. Enzyme replacement and substrate reduction therapy for Gaucher disease. Cochrane Database Syst. Rev. 2015, CD010324 (2015).","journal-title":"Cochrane Database Syst. Rev."},{"key":"999_CR43","doi-asserted-by":"publisher","first-page":"684067","DOI":"10.3389\/fgene.2021.684067","volume":"12","author":"EG Woo","year":"2021","unstructured":"Woo, E. G., Tayebi, N. & Sidransky, E. Next-generation sequencing analysis of GBA1: the challenge of detecting complex recombinant alleles. Front. Genet. 12, 684067 (2021).","journal-title":"Front. Genet."},{"key":"999_CR44","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/s42003-022-03610-7","volume":"5","author":"M Toffoli","year":"2022","unstructured":"Toffoli, M. et al. Comprehensive short and long read sequencing analysis for the Gaucher and Parkinson\u2019s disease-associated GBA gene. Commun. Biol. 5, 670 (2022).","journal-title":"Commun. Biol."},{"key":"999_CR45","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jmoldx.2017.05.005","volume":"19","author":"S Zampieri","year":"2017","unstructured":"Zampieri, S., Cattarossi, S., Bembi, B. & Dardis, A. GBA analysis in next-generation era: pitfalls, challenges, and possible solutions. J. Mol. Diagn. 19, 733\u2013741 (2017).","journal-title":"J. Mol. Diagn."},{"key":"999_CR46","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.bcmd.2010.10.007","volume":"46","author":"M Biegstraaten","year":"2011","unstructured":"Biegstraaten, M. et al. A monozygotic twin pair with highly discordant Gaucher phenotypes. Blood Cell Mol. Dis. 46, 39\u201341 (2011).","journal-title":"Blood Cell Mol. Dis."},{"key":"999_CR47","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ymgme.2019.05.011","volume":"127","author":"A Kurolap","year":"2019","unstructured":"Kurolap, A. et al. Gaucher disease type 3c: new patients with unique presentations and review of the literature. Mol. Genet. Metab. 127, 138\u2013146 (2019).","journal-title":"Mol. Genet. Metab."},{"key":"999_CR48","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000104","volume":"2","author":"V Mallett","year":"2016","unstructured":"Mallett, V. et al. GBA p.T369M substitution in Parkinson disease: polymorphism or association? A meta-analysis. Neurol. Genet. 2, e104 (2016).","journal-title":"Neurol. Genet."},{"key":"999_CR49","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1034\/j.1399-0004.2002.610106.x","volume":"61","author":"JK Park","year":"2002","unstructured":"Park, J. K. et al. The E326K mutation and Gaucher disease: mutation or polymorphism? Clin. Genet. 61, 32\u201334 (2002).","journal-title":"Clin. Genet."},{"key":"999_CR50","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/mds.25248","volume":"28","author":"R Duran","year":"2013","unstructured":"Duran, R. et al. The glucocerobrosidase E326K variant predisposes to Parkinson\u2019s disease, but does not cause Gaucher\u2019s disease. Mov. Disord. 28, 232\u2013236 (2013).","journal-title":"Mov. Disord."},{"key":"999_CR51","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1002\/ajh.24056","volume":"90","author":"J Charrow","year":"2015","unstructured":"Charrow, J. & Scott, C. R. Long-term treatment outcomes in Gaucher disease. Am. J. Hematol. 90, S19\u2013S24 (2015).","journal-title":"Am. J. Hematol."},{"key":"999_CR52","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ymgme.2016.12.001","volume":"120","author":"A El-Beshlawy","year":"2017","unstructured":"El-Beshlawy, A. et al. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry. Mol. Genet. Metab. 120, 47\u201356 (2017).","journal-title":"Mol. Genet. Metab."},{"key":"999_CR53","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","volume":"385","author":"TM Cox","year":"2015","unstructured":"Cox, T. M. et al. Eliglustat compared with imiglucerase in patients with Gaucher\u2019s disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. Lancet 385, 2355\u20132362 (2015).","journal-title":"Lancet"},{"key":"999_CR54","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","volume":"355","author":"T Cox","year":"2000","unstructured":"Cox, T. et al. Novel oral treatment of Gaucher\u2019s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355, 1481\u20131485 (2000).","journal-title":"Lancet"},{"key":"999_CR55","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1002\/ajh.27347","volume":"99","author":"PK Mistry","year":"2024","unstructured":"Mistry, P. K. et al. Long-term effectiveness of eliglustat treatment: a real-world analysis from the International Collaborative Gaucher Group Gaucher Registry. Am. J. Hematol. 99, 1500\u20131510 (2024).","journal-title":"Am. J. Hematol."},{"key":"999_CR56","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1093\/brain\/awac379","volume":"146","author":"R Schiffmann","year":"2023","unstructured":"Schiffmann, R. et al. Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial. Brain 146, 461\u2013474 (2023).","journal-title":"Brain"},{"key":"999_CR57","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1002\/cbic.200900442","volume":"10","author":"Z Luan","year":"2009","unstructured":"Luan, Z. et al. Chaperone activity of bicyclic nojirimycin analogues for Gaucher mutations in comparison with N-(n-nonyl)deoxynojirimycin. Chembiochem 10, 2780\u20132792 (2009).","journal-title":"Chembiochem"},{"key":"999_CR58","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3389\/fcell.2020.00271","volume":"8","author":"TU Han","year":"2020","unstructured":"Han, T. U., Sam, R. & Sidransky, E. Small molecule chaperones for the treatment of Gaucher disease and GBA1-associated Parkinson disease. Front. Cell Dev. Biol. 8, 271 (2020).","journal-title":"Front. Cell Dev. Biol."},{"issue":"9","key":"999_CR59","doi-asserted-by":"publisher","first-page":"4479","DOI":"10.1021\/jm300342q","volume":"55","author":"A Trapero","year":"2012","unstructured":"Trapero, A., Gonz\u00e1lez-Bulnes, P., Butters, T. D. & Llebaria, A. Potent aminocyclitol glucocerebrosidase inhibitors are subnanomolar pharmacological chaperones for treating Gaucher disease. J. Med. Chem. 55,\u00a04479\u20134488 (2012).","journal-title":"J. Med. Chem."},{"key":"999_CR60","doi-asserted-by":"publisher","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","volume":"284","author":"GH Maegawa","year":"2009","unstructured":"Maegawa, G. H. et al. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J. Biol. Chem. 284, 23502\u201323516 (2009).","journal-title":"J. Biol. Chem."},{"key":"999_CR61","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/acn3.292","volume":"3","author":"A Narita","year":"2016","unstructured":"Narita, A. et al. Ambroxol chaperone therapy for neuronopathic Gaucher disease: a pilot study. Ann. Clin. Transl. Neurol. 3, 200\u2013215 (2016).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"999_CR62","doi-asserted-by":"publisher","first-page":"6732","DOI":"10.3390\/ijms24076732","volume":"24","author":"M Istaiti","year":"2023","unstructured":"Istaiti, M. et al. High-dose ambroxol therapy in type 1 Gaucher disease focusing on patients with poor response to enzyme replacement therapy or substrate reduction therapy. Int. J. Mol. Sci. 24, 6732 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"999_CR63","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S1474-4422(19)30287-X","volume":"19","author":"C Blauwendraat","year":"2020","unstructured":"Blauwendraat, C., Nalls, M. A. & Singleton, A. B. The genetic architecture of Parkinson\u2019s disease. Lancet Neurol. 19, 170\u2013178 (2020).","journal-title":"Lancet Neurol."},{"key":"999_CR64","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/ana.24777","volume":"80","author":"R Cilia","year":"2016","unstructured":"Cilia, R. et al. Survival and dementia in GBA-associated Parkinson\u2019s disease: The mutation matters. Ann. Neurol. 80, 662\u2013673 (2016).","journal-title":"Ann. Neurol."},{"key":"999_CR65","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1212\/01.wnl.0000304039.11891.29","volume":"70","author":"Z Gan-Or","year":"2008","unstructured":"Gan-Or, Z. et al. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 70, 2277\u20132283 (2008).","journal-title":"Neurology"},{"key":"999_CR66","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/ana.22687","volume":"71","author":"N Pankratz","year":"2012","unstructured":"Pankratz, N. et al. Meta-analysis of Parkinson\u2019s disease: identification of a novel locus, RIT2. Ann. Neurol. 71, 370\u2013384 (2012).","journal-title":"Ann. Neurol."},{"key":"999_CR67","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S1474-4422(23)00283-1","volume":"22","author":"M Rizig","year":"2023","unstructured":"Rizig, M. et al. Identification of genetic risk loci and causal insights associated with Parkinson\u2019s disease in African and African admixed populations: a genome-wide association study. Lancet Neurol. 22, 1015\u20131025 (2023).","journal-title":"Lancet Neurol."},{"key":"999_CR68","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/acn3.185","volume":"2","author":"J Mitsui","year":"2015","unstructured":"Mitsui, J. et al. Variants associated with Gaucher disease in multiple system atrophy. Ann. Clin. Transl. Neurol. 2, 417\u2013426 (2015).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"999_CR69","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/mdc3.12481","volume":"4","author":"M Sklerov","year":"2017","unstructured":"Sklerov, M. et al. Frequency of GBA variants in autopsy-proven multiple system atrophy. Mov. Disord. Clin. Pract. 4, 574\u2013581 (2017).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"999_CR70","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.parkreldis.2020.06.007","volume":"77","author":"AI Wernick","year":"2020","unstructured":"Wernick, A. I. et al. GBA variation and susceptibility to multiple system atrophy. Parkinsonism Relat. Disord. 77, 64\u201369 (2020).","journal-title":"Parkinsonism Relat. Disord."},{"key":"999_CR71","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1001\/jamaneurol.2014.313","volume":"71","author":"RN Alcalay","year":"2014","unstructured":"Alcalay, R. N. et al. Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol. 71, 752\u2013757 (2014).","journal-title":"JAMA Neurol."},{"key":"999_CR72","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10545-010-9055-0","volume":"33","author":"G Bultron","year":"2010","unstructured":"Bultron, G. et al. The risk of Parkinson\u2019s disease in type 1 Gaucher disease. J. Inherit. Metab. Dis. 33, 167\u2013173 (2010).","journal-title":"J. Inherit. Metab. Dis."},{"key":"999_CR73","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.bcmd.2010.10.006","volume":"46","author":"B Rosenbloom","year":"2011","unstructured":"Rosenbloom, B. et al. The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry. Blood Cell Mol. Dis. 46, 95\u2013102 (2011).","journal-title":"Blood Cell Mol. Dis."},{"key":"999_CR74","doi-asserted-by":"publisher","first-page":"106553","DOI":"10.1016\/j.nbd.2024.106553","volume":"198","author":"A Ali","year":"2024","unstructured":"Ali, A., Holman, A. P., Rodriguez, A., Osborne, L. & Kurouski, D. Elucidating the mechanisms of \u03b1-synuclein-lipid interactions using site-directed mutagenesis. Neurobiol. Dis. 198, 106553 (2024).","journal-title":"Neurobiol. Dis."},{"key":"999_CR75","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.neuron.2017.12.012","volume":"97","author":"F Zunke","year":"2018","unstructured":"Zunke, F. et al. Reversible conformational conversion of \u03b1-synuclein into toxic assemblies by glucosylceramide. Neuron 97, 92\u2013107.e10 (2018).","journal-title":"Neuron"},{"key":"999_CR76","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1093\/hmg\/ddq292","volume":"19","author":"I Ron","year":"2010","unstructured":"Ron, I., Rapaport, D. & Horowitz, M. Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Parkinson disease and Gaucher disease. Hum. Mol. Genet. 19, 3771\u20133781 (2010).","journal-title":"Hum. Mol. Genet."},{"key":"999_CR77","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1212\/01.wnl.0000230215.41296.18","volume":"67","author":"O Goker-Alpan","year":"2006","unstructured":"Goker-Alpan, O. et al. Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology 67, 908\u2013910 (2006).","journal-title":"Neurology"},{"key":"999_CR78","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1212\/01.wnl.0000327823.81237.d1","volume":"72","author":"WC Nichols","year":"2009","unstructured":"Nichols, W. C. et al. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology 72, 310\u2013316 (2009).","journal-title":"Neurology"},{"key":"999_CR79","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14387","volume":"30","author":"J Ren","year":"2024","unstructured":"Ren, J. et al. Comparing the effects of GBA variants and onset age on clinical features and progression in Parkinson\u2019s disease. CNS Neurosci. Ther. 30, e14387 (2024).","journal-title":"CNS Neurosci. Ther."},{"key":"999_CR80","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1136\/jnnp-2017-317348","volume":"89","author":"N Malek","year":"2018","unstructured":"Malek, N. et al. Features of GBA-associated Parkinson\u2019s disease at presentation in the UK Tracking Parkinson\u2019s study. J. Neurol. Neurosurg. Psychiatry 89, 702\u2013709 (2018).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"999_CR81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0167749","volume":"11","author":"S Jesus","year":"2016","unstructured":"Jesus, S. et al. GBA variants influence motor and non-motor features of Parkinson\u2019s disease. PLoS ONE 11, e0167749 (2016).","journal-title":"PLoS ONE"},{"key":"999_CR82","doi-asserted-by":"publisher","first-page":"106343","DOI":"10.1016\/j.nbd.2023.106343","volume":"188","author":"M Toffoli","year":"2023","unstructured":"Toffoli, M. et al. Phenotypic effect of GBA1 variants in individuals with and without Parkinson\u2019s disease: The RAPSODI study. Neurobiol. Dis. 188, 106343 (2023).","journal-title":"Neurobiol. Dis."},{"key":"999_CR83","doi-asserted-by":"publisher","first-page":"1091919","DOI":"10.3389\/fnagi.2023.1091919","volume":"15","author":"J Ren","year":"2023","unstructured":"Ren, J. et al. Association of GBA genotype with motor and cognitive decline in Chinese Parkinson\u2019s disease patients. Front. Aging Neurosci. 15, 1091919 (2023).","journal-title":"Front. Aging Neurosci."},{"key":"999_CR84","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1212\/WNL.0b013e318225ab77","volume":"77","author":"K Brockmann","year":"2011","unstructured":"Brockmann, K. et al. GBA-associated PD presents with nonmotor characteristics. Neurology 77, 276\u2013280 (2011).","journal-title":"Neurology"},{"key":"999_CR85","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000523","volume":"6","author":"L Straniero","year":"2020","unstructured":"Straniero, L. et al. The SPID-GBA study: sex distribution, penetrance, incidence, and dementia in GBA-PD. Neurol. Genet. 6, e523 (2020).","journal-title":"Neurol. Genet."},{"key":"999_CR86","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1002\/mds.29197","volume":"37","author":"RA Ortega","year":"2022","unstructured":"Ortega, R. A. et al. Differences in sex-specific frequency of glucocerebrosidase variant carriers and familial Parkinsonism. Mov. Disord. 37, 2217\u20132225 (2022).","journal-title":"Mov. Disord."},{"key":"999_CR87","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/mds.29348","volume":"38","author":"A Thaler","year":"2023","unstructured":"Thaler, A., Mirelman, A. & Alcalay, R. N. Differences in sex-specific frequency of glucocerebrosidase variant carriers and familial Parkinsonism. Mov. Disord. 38, 713\u2013714 (2023).","journal-title":"Mov. Disord."},{"key":"999_CR88","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1007\/s10072-021-05230-1","volume":"42","author":"Q Li","year":"2021","unstructured":"Li, Q., Jing, Y., Lun, P., Liu, X. & Sun, P. Association of gender and age at onset with glucocerebrosidase associated Parkinson\u2019s disease: a systematic review and meta-analysis. Neurol. Sci. 42, 2261\u20132271 (2021).","journal-title":"Neurol. Sci."},{"key":"999_CR89","doi-asserted-by":"publisher","first-page":"105919","DOI":"10.1016\/j.parkreldis.2023.105919","volume":"117","author":"C Panteghini","year":"2023","unstructured":"Panteghini, C. et al. Sex distribution and classification of GBA1 variants in an Italian cohort of Parkinson\u2019s disease patients analyzed over the last seventeen years. Parkinsonism Relat. Disord. 117, 105919 (2023).","journal-title":"Parkinsonism Relat. Disord."},{"key":"999_CR90","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/ene.13776","volume":"26","author":"M Zimmermann","year":"2019","unstructured":"Zimmermann, M. et al. Patient\u2019s perception: shorter and more severe prodromal phase in GBA-associated PD. Eur. J. Neurol. 26, 694\u2013698 (2019).","journal-title":"Eur. J. Neurol."},{"key":"999_CR91","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000057","volume":"2","author":"G Lopez","year":"2016","unstructured":"Lopez, G. et al. Clinical course and prognosis in patients with Gaucher disease and parkinsonism. Neurol. Genet. 2, e57 (2016).","journal-title":"Neurol. Genet."},{"key":"999_CR92","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/mds.27989","volume":"35","author":"T Simuni","year":"2020","unstructured":"Simuni, T. et al. Clinical and dopamine transporter imaging characteristics of leucine rich repeat kinase 2 (LRRK2) and glucosylceramidase beta (GBA) Parkinson\u2019s disease participants in the Parkinson\u2019s Progression Markers Initiative: a cross-sectional study. Mov. Disord. 35, 833\u2013844 (2020).","journal-title":"Mov. Disord."},{"key":"999_CR93","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41588-021-00785-3","volume":"53","author":"R Chia","year":"2021","unstructured":"Chia, R. et al. Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nat. Genet. 53, 294\u2013303 (2021).","journal-title":"Nat. Genet."},{"key":"999_CR94","doi-asserted-by":"publisher","first-page":"104856","DOI":"10.1016\/j.neubiorev.2022.104856","volume":"141","author":"S Gaubert","year":"2022","unstructured":"Gaubert, S. et al. Exploring the link between GBA1 mutations and Dementia with Lewy bodies, a mini-review. Neurosci. Biobehav. Rev. 141, 104856 (2022).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"999_CR95","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ymgme.2004.04.011","volume":"82","author":"K Wong","year":"2004","unstructured":"Wong, K. et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol. Genet. Metab. 82, 192\u2013207 (2004).","journal-title":"Mol. Genet. Metab."},{"key":"999_CR96","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1002\/mds.28200","volume":"35","author":"R Balestrino","year":"2020","unstructured":"Balestrino, R. et al. Penetrance of glucocerebrosidase (GBA) mutations in Parkinson\u2019s disease: a kin cohort study. Mov. Disord. 35, 2111\u20132114 (2020).","journal-title":"Mov. Disord."},{"key":"999_CR97","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jamaneurol.2014.2950","volume":"72","author":"M Beavan","year":"2015","unstructured":"Beavan, M. et al. Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort. JAMA Neurol. 72, 201\u2013208 (2015).","journal-title":"JAMA Neurol."},{"key":"999_CR98","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1002\/mds.27775","volume":"34","author":"S Mullin","year":"2019","unstructured":"Mullin, S. et al. Evolution and clustering of prodromal parkinsonian features in GBA1 carriers. Mov. Disord. 34, 1365\u20131373 (2019).","journal-title":"Mov. Disord."},{"key":"999_CR99","doi-asserted-by":"publisher","first-page":"12211","DOI":"10.3390\/ijms232012211","volume":"23","author":"M Becker-Cohen","year":"2022","unstructured":"Becker-Cohen, M. et al. A comprehensive assessment of qualitative and quantitative prodromal parkinsonian features in carriers of Gaucher disease-identifying those at the greatest risk. Int. J. Mol. Sci. 23, 12211 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"999_CR100","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1136\/jnnp-2019-320394","volume":"90","author":"M Avenali","year":"2019","unstructured":"Avenali, M. et al. Evolution of prodromal parkinsonian features in a cohort of GBA mutation-positive individuals: a 6-year longitudinal study. J. Neurol. Neurosurg. Psychiatry 90, 1091\u20131097 (2019).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"999_CR101","doi-asserted-by":"publisher","first-page":"1039214","DOI":"10.3389\/fneur.2022.1039214","volume":"13","author":"GJ Lopez","year":"2022","unstructured":"Lopez, G. J. et al. Longitudinal evaluation of olfactory function in individuals with Gaucher disease and GBA1 mutation carriers with and without Parkinson\u2019s disease. Front. Neurol. 13, 1039214 (2022).","journal-title":"Front. Neurol."},{"key":"999_CR102","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1002\/mds.29047","volume":"37","author":"M Filippi","year":"2022","unstructured":"Filippi, M., Balestrino, R., Basaia, S. & Agosta, F. Neuroimaging in glucocerebrosidase-associated parkinsonism: a systematic review. Mov. Disord. 37, 1375\u20131393 (2022).","journal-title":"Mov. Disord."},{"key":"999_CR103","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1093\/brain\/aws174","volume":"135","author":"O Goker-Alpan","year":"2012","unstructured":"Goker-Alpan, O. et al. The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow. Brain 135, 2440\u20132448 (2012).","journal-title":"Brain"},{"key":"999_CR104","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1093\/brain\/awad323","volume":"147","author":"S Slingerland","year":"2024","unstructured":"Slingerland, S. et al. Cholinergic innervation topography in GBA-associated de novo Parkinson\u2019s disease patients. Brain 147, 900\u2013910 (2024).","journal-title":"Brain"},{"key":"999_CR105","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1002\/mds.28225","volume":"35","author":"A Greuel","year":"2020","unstructured":"Greuel, A. et al. GBA variants in Parkinson\u2019s disease: clinical, metabolomic, and multimodal neuroimaging phenotypes. Mov. Disord. 35, 2201\u20132210 (2020).","journal-title":"Mov. Disord."},{"key":"999_CR106","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/ana.25692","volume":"87","author":"G Lopez","year":"2020","unstructured":"Lopez, G. et al. Longitudinal positron emission tomography of dopamine synthesis in subjects with GBA1 mutations. Ann. Neurol. 87, 652\u2013657 (2020).","journal-title":"Ann. Neurol."},{"key":"999_CR107","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/acn3.644","volume":"5","author":"K Marek","year":"2018","unstructured":"Marek, K. et al. The Parkinson\u2019s Progression Markers Initiative (PPMI) \u2013 establishing a PD biomarker cohort. Ann. Clin. Transl. Neurol. 5, 1460\u20131477 (2018).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"999_CR108","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S1474-4422(19)30319-9","volume":"19","author":"T Simuni","year":"2020","unstructured":"Simuni, T. et al. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson\u2019s Progression Markers Initiative (PPMI): a cross-sectional study. Lancet Neurol. 19, 71\u201380 (2020).","journal-title":"Lancet Neurol."},{"key":"999_CR109","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/mds.28375","volume":"36","author":"S Mullin","year":"2021","unstructured":"Mullin, S. et al. Brain microglial activation increased in glucocerebrosidase (GBA) mutation carriers without Parkinson\u2019s disease. Mov. Disord. 36, 774\u2013779 (2021).","journal-title":"Mov. Disord."},{"key":"999_CR110","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/S1474-4422(08)70239-4","volume":"7","author":"D Berg","year":"2008","unstructured":"Berg, D., Godau, J. & Walter, U. Transcranial sonography in movement disorders. Lancet Neurol. 7, 1044\u20131055 (2008).","journal-title":"Lancet Neurol."},{"key":"999_CR111","doi-asserted-by":"publisher","DOI":"10.1038\/srep20863","volume":"6","author":"DH Li","year":"2016","unstructured":"Li, D. H., He, Y. C., Liu, J. & Chen, S. D. Diagnostic accuracy of transcranial sonography of the substantia nigra in Parkinson\u2019s disease: a systematic review and meta-analysis. Sci. Rep. 6, 20863 (2016).","journal-title":"Sci. Rep."},{"key":"999_CR112","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.parkreldis.2012.12.006","volume":"19","author":"N Kresojevic","year":"2013","unstructured":"Kresojevic, N. et al. Transcranial sonography in patients with Parkinson\u2019s disease with glucocerebrosidase mutations. Parkinsonism Relat. Disord. 19, 431\u2013435 (2013).","journal-title":"Parkinsonism Relat. Disord."},{"key":"999_CR113","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1002\/mds.23046","volume":"25","author":"R Saunders-Pullman","year":"2010","unstructured":"Saunders-Pullman, R. et al. Gaucher disease ascertained through a Parkinson\u2019s center: imaging and clinical characterization. Mov. Disord. 25, 1364\u20131372 (2010).","journal-title":"Mov. Disord."},{"key":"999_CR114","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/mds.28852","volume":"37","author":"DP Eisenberg","year":"2022","unstructured":"Eisenberg, D. P., Lopez, G., Gregory, M. D., Berman, K. F. & Sidransky, E. Comparison of transcranial sonography and [18F]-fluorodopa PET imaging in GBA1 mutation carriers. Mov. Disord. 37, 629\u2013634 (2022).","journal-title":"Mov. Disord."},{"key":"999_CR115","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/ajh.24491","volume":"91","author":"V Murugesan","year":"2016","unstructured":"Murugesan, V. et al. Glucosylsphingosine is a key biomarker of Gaucher disease. Am. J. Hematol. 91, 1082\u20131089 (2016).","journal-title":"Am. J. Hematol."},{"key":"999_CR116","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ymgme.2017.08.005","volume":"122","author":"D Elstein","year":"2017","unstructured":"Elstein, D. et al. Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naive and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: data from phase 3 clinical trials. Mol. Genet. Metab. 122, 113\u2013120 (2017).","journal-title":"Mol. Genet. Metab."},{"key":"999_CR117","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/mds.28472","volume":"36","author":"S Lerche","year":"2021","unstructured":"Lerche, S. et al. The mutation matters: CSF profiles of GCase, sphingolipids, \u03b1-synuclein in PDGBA. Mov. Disord. 36, 1216\u20131228 (2021).","journal-title":"Mov. Disord."},{"key":"999_CR118","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1002\/mds.27136","volume":"32","author":"L Parnetti","year":"2017","unstructured":"Parnetti, L. et al. Cerebrospinal fluid \u03b2-glucocerebrosidase activity is reduced in Parkinson\u2019s disease patients. Mov. Disord. 32, 1423\u20131431 (2017).","journal-title":"Mov. Disord."},{"key":"999_CR119","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/mds.28846","volume":"37","author":"M Surface","year":"2022","unstructured":"Surface, M. et al. Plasma glucosylsphingosine in GBA1 mutation carriers with and without Parkinson\u2019s disease. Mov. Disord. 37, 416\u2013421 (2022).","journal-title":"Mov. Disord."},{"key":"999_CR120","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/mds.28929","volume":"37","author":"N Omer","year":"2022","unstructured":"Omer, N. et al. Glucocerebrosidase activity is not associated with Parkinson\u2019s disease risk or severity. Mov. Disord. 37, 651\u2013652 (2022).","journal-title":"Mov. Disord."},{"key":"999_CR121","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/mds.29360","volume":"38","author":"JM den Heijer","year":"2023","unstructured":"den Heijer, J. M. et al. A biomarker study in patients with GBA1-Parkinson\u2019s disease and healthy controls. Mov. Disord. 38, 783\u2013795 (2023).","journal-title":"Mov. Disord."},{"key":"999_CR122","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","volume":"22","author":"A Siderowf","year":"2023","unstructured":"Siderowf, A. et al. Assessment of heterogeneity among participants in the Parkinson\u2019s Progression Markers Initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 22, 407\u2013417 (2023).","journal-title":"Lancet Neurol."},{"key":"999_CR123","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1093\/brain\/awp044","volume":"132","author":"J Neumann","year":"2009","unstructured":"Neumann, J. et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson\u2019s disease. Brain 132, 1783\u20131794 (2009).","journal-title":"Brain"},{"key":"999_CR124","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1001\/archneurol.2009.54","volume":"66","author":"LN Clark","year":"2009","unstructured":"Clark, L. N. et al. Association of glucocerebrosidase mutations with dementia with Lewy bodies. Arch. Neurol. 66, 578\u2013583 (2009).","journal-title":"Arch. Neurol."},{"key":"999_CR125","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13024-019-0339-z","volume":"14","author":"M Huebecker","year":"2019","unstructured":"Huebecker, M. et al. Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson\u2019s disease. Mol. Neurodegener. 14, 40 (2019).","journal-title":"Mol. Neurodegener."},{"key":"999_CR126","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/brain\/awt367","volume":"137","author":"KE Murphy","year":"2014","unstructured":"Murphy, K. E. et al. Reduced glucocerebrosidase is associated with increased \u03b1-synuclein in sporadic Parkinson\u2019s disease. Brain 137, 834\u2013848 (2014).","journal-title":"Brain"},{"key":"999_CR127","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/acn3.177","volume":"2","author":"EM Rocha","year":"2015","unstructured":"Rocha, E. M. et al. Progressive decline of glucocerebrosidase in aging and Parkinson\u2019s disease. Ann. Clin. Transl. Neurol. 2, 433\u2013438 (2015).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"999_CR128","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.conb.2021.11.004","volume":"72","author":"I Milenkovic","year":"2022","unstructured":"Milenkovic, I., Blumenreich, S. & Futerman, A. H. GBA mutations, glucosylceramide and Parkinson\u2019s disease. Curr. Opin. Neurobiol. 72, 148\u2013154 (2022).","journal-title":"Curr. Opin. Neurobiol."},{"key":"999_CR129","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S1096-7192(02)00117-8","volume":"76","author":"E Orvisky","year":"2002","unstructured":"Orvisky, E. et al. Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype. Mol. Genet. Metab. 76, 262\u2013270 (2002).","journal-title":"Mol. Genet. Metab."},{"key":"999_CR130","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1002\/mds.26278","volume":"30","author":"ME Gegg","year":"2015","unstructured":"Gegg, M. E. et al. No evidence for substrate accumulation in Parkinson brains with GBA mutations. Mov. Disord. 30, 1085\u20131089 (2015).","journal-title":"Mov. Disord."},{"key":"999_CR131","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41531-023-00517-w","volume":"9","author":"CEG Leyns","year":"2023","unstructured":"Leyns, C. E. G. et al. Glucocerebrosidase activity and lipid levels are related to protein pathologies in Parkinson\u2019s disease. NPJ Parkinsons Dis. 9, 74 (2023).","journal-title":"NPJ Parkinsons Dis."},{"key":"999_CR132","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41531-022-00363-2","volume":"8","author":"S Blumenreich","year":"2022","unstructured":"Blumenreich, S. et al. Elevation of gangliosides in four brain regions from Parkinson\u2019s disease patients with a GBA mutation. NPJ Parkinsons Dis. 8, 99 (2022).","journal-title":"NPJ Parkinsons Dis."},{"key":"999_CR133","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s00401-024-02699-w","volume":"147","author":"RL Walton","year":"2024","unstructured":"Walton, R. L. et al. Role of GBA variants in Lewy body disease neuropathology. Acta Neuropathol. 147, 54 (2024).","journal-title":"Acta Neuropathol."},{"key":"999_CR134","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1002\/humu.21566","volume":"32","author":"A Velayati","year":"2011","unstructured":"Velayati, A. et al. A mutation in SCARB2 is a modifier in Gaucher disease. Hum. Mutat. 32, 1232\u20131238 (2011).","journal-title":"Hum. Mutat."},{"key":"999_CR135","doi-asserted-by":"publisher","first-page":"4934","DOI":"10.1073\/pnas.1400768111","volume":"111","author":"PK Mistry","year":"2014","unstructured":"Mistry, P. K. et al. Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease. Proc. Natl Acad. Sci. USA 111, 4934\u20134939 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"999_CR136","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-151","volume":"8","author":"Y Yildiz","year":"2013","unstructured":"Yildiz, Y. et al. Functional and genetic characterization of the non-lysosomal glucosylceramidase 2 as a modifier for Gaucher disease. Orphanet J. Rare Dis. 8, 151 (2013).","journal-title":"Orphanet J. Rare Dis."},{"key":"999_CR137","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/ajh.23118","volume":"87","author":"CK Zhang","year":"2012","unstructured":"Zhang, C. K. et al. Genome-wide association study of N370S homozygous Gaucher disease reveals the candidacy of CLN8 gene as a genetic modifier contributing to extreme phenotypic variation. Am. J. Hematol. 87, 377\u2013383 (2012).","journal-title":"Am. J. Hematol."},{"key":"999_CR138","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/s41556-018-0228-7","volume":"20","author":"A di Ronza","year":"2018","unstructured":"di Ronza, A. et al. CLN8 is an endoplasmic reticulum cargo receptor that regulates lysosome biogenesis. Nat. Cell Biol. 20, 1370\u20131377 (2018).","journal-title":"Nat. Cell Biol."},{"key":"999_CR139","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1016\/j.celrep.2016.07.085","volume":"16","author":"AD Klein","year":"2016","unstructured":"Klein, A. D. et al. Identification model of Gaucher disease. Cell Rep. 16, 2546\u20132553 (2016).","journal-title":"Cell Rep."},{"key":"999_CR140","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/brain\/awz350","volume":"143","author":"C Blauwendraat","year":"2020","unstructured":"Blauwendraat, C. et al. Genetic modifiers of risk and age at onset in GBA associated Parkinson\u2019s disease and Lewy body dementia. Brain 143, 234\u2013248 (2020).","journal-title":"Brain"},{"key":"999_CR141","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2108489118","volume":"118","author":"K Fredriksen","year":"2021","unstructured":"Fredriksen, K. et al. Pathological \u03b1-syn aggregation is mediated by glycosphingolipid chain length and the physiological state of \u03b1-syn in vivo. Proc. Natl Acad. Sci. USA 118, e2108489118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"999_CR142","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.neuron.2019.12.004","volume":"105","author":"MX Henderson","year":"2020","unstructured":"Henderson, M. X. et al. Glucocerebrosidase activity modulates neuronal susceptibility to pathological \u03b1-synuclein insult. Neuron 105, 822\u2013836.e7 (2020).","journal-title":"Neuron"},{"key":"999_CR143","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/ana.26166","volume":"90","author":"J Jo","year":"2021","unstructured":"Jo, J. et al. Lewy body-like inclusions in human midbrain organoids carrying glucocerebrosidase and \u03b1-synuclein mutations. Ann. Neurol. 90, 490\u2013505 (2021).","journal-title":"Ann. Neurol."},{"key":"999_CR144","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","volume":"146","author":"JR Mazzulli","year":"2011","unstructured":"Mazzulli, J. R. et al. Gaucher disease glucocerebrosidase and \u03b1-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146, 37\u201352 (2011).","journal-title":"Cell"},{"key":"999_CR145","doi-asserted-by":"publisher","first-page":"11854","DOI":"10.1021\/acsnano.1c02957","volume":"15","author":"A Paul","year":"2021","unstructured":"Paul, A. et al. Glucosylceramide associated with Gaucher disease forms amyloid-like twisted ribbon fibrils that induce \u03b1-synuclein aggregation. ACS Nano 15, 11854\u201311868 (2021).","journal-title":"ACS Nano"},{"key":"999_CR146","doi-asserted-by":"publisher","first-page":"9617","DOI":"10.1523\/JNEUROSCI.1525-17.2017","volume":"37","author":"YV Taguchi","year":"2017","unstructured":"Taguchi, Y. V. et al. Glucosylsphingosine promotes \u03b1-synuclein pathology in mutant GBA-associated Parkinson\u2019s disease. J. Neurosci. 37, 9617\u20139631 (2017).","journal-title":"J. Neurosci."},{"key":"999_CR147","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/brain\/awab371","volume":"145","author":"C Galvagnion","year":"2022","unstructured":"Galvagnion, C. et al. Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote \u03b1-synuclein aggregation. Brain 145, 1038\u20131051 (2022).","journal-title":"Brain"},{"key":"999_CR148","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5028","volume":"5","author":"DC Schondorf","year":"2014","unstructured":"Schondorf, D. C. et al. iPSC-derived neurons from GBA1-associated Parkinson\u2019s disease patients show autophagic defects and impaired calcium homeostasis. Nat. Commun. 5, 4028 (2014).","journal-title":"Nat. Commun."},{"key":"999_CR149","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.stemcr.2016.01.013","volume":"6","author":"HJ Fernandes","year":"2016","unstructured":"Fernandes, H. J. et al. ER stress and autophagic perturbations lead to elevated extracellular \u03b1-synuclein in GBA-N370S Parkinson\u2019s iPSC-derived dopamine neurons. Stem Cell Rep. 6, 342\u2013356 (2016).","journal-title":"Stem Cell Rep."},{"key":"999_CR150","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.neulet.2019.05.027","volume":"706","author":"M Zurbruegg","year":"2019","unstructured":"Zurbruegg, M., Chan, M. Y. & Svenningsson, P. GBA RNAi but not catalytic inhibition of glucocerebrosidase with conduritol-\u03b2-epoxide increases levels of total \u03b1-synuclein in SH-SY5Y cells. Neurosci. Lett. 706, 217\u2013222 (2019).","journal-title":"Neurosci. Lett."},{"key":"999_CR151","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1093\/hmg\/ddz005","volume":"28","author":"G Maor","year":"2019","unstructured":"Maor, G., Rapaport, D. & Horowitz, M. The effect of mutant GBA1 on accumulation and aggregation of \u03b1-synuclein. Hum. Mol. Genet. 28, 1768\u20131781 (2019).","journal-title":"Hum. Mol. Genet."},{"key":"999_CR152","first-page":"2712","volume":"25","author":"G Maor","year":"2016","unstructured":"Maor, G. et al. The contribution of mutant GBA to the development of Parkinson disease in Drosophila. Hum. Mol. Genet. 25, 2712\u20132727 (2016).","journal-title":"Hum. Mol. Genet."},{"key":"999_CR153","doi-asserted-by":"publisher","first-page":"12101","DOI":"10.1073\/pnas.1108197108","volume":"108","author":"SP Sardi","year":"2011","unstructured":"Sardi, S. P. et al. CNS expression of glucocerebrosidase corrects \u03b1-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proc. Natl Acad. Sci. USA 108, 12101\u201312106 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"999_CR154","doi-asserted-by":"publisher","first-page":"112180","DOI":"10.1016\/j.celrep.2023.112180","volume":"42","author":"H Bogetofte","year":"2023","unstructured":"Bogetofte, H. et al. Post-translational proteomics platform identifies neurite outgrowth impairments in Parkinson\u2019s disease GBA-N370S dopamine neurons. Cell Rep. 42, 112180 (2023).","journal-title":"Cell Rep."},{"key":"999_CR155","first-page":"773","volume":"32","author":"LJ Smith","year":"2023","unstructured":"Smith, L. J., Bolsinger, M. M., Chau, K. Y., Gegg, M. E. & Schapira, A. H. V. The GBA variant E326K is associated with \u03b1-synuclein aggregation and lipid droplet accumulation in human cell lines. Hum. Mol. Genet. 32, 773\u2013789 (2023).","journal-title":"Hum. Mol. Genet."},{"key":"999_CR156","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abm6393","volume":"8","author":"SH Kuo","year":"2022","unstructured":"Kuo, S. H. et al. Mutant glucocerebrosidase impairs \u03b1-synuclein degradation by blockade of chaperone-mediated autophagy. Sci. Adv. 8, eabm6393 (2022).","journal-title":"Sci. Adv."},{"key":"999_CR157","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22113-3","volume":"12","author":"S Kim","year":"2021","unstructured":"Kim, S., Wong, Y. C., Gao, F. & Krainc, D. Dysregulation of mitochondria-lysosome contacts by GBA1 dysfunction in dopaminergic neuronal models of Parkinson\u2019s disease. Nat. Commun. 12, 1807 (2021).","journal-title":"Nat. Commun."},{"key":"999_CR158","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nature25486","volume":"554","author":"YC Wong","year":"2018","unstructured":"Wong, Y. C., Ysselstein, D. & Krainc, D. Mitochondria-lysosome contacts regulate mitochondrial fission via RAB7 GTP hydrolysis. Nature 554, 382\u2013386 (2018).","journal-title":"Nature"},{"key":"999_CR159","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1016\/j.neuron.2022.04.020","volume":"110","author":"S Kim","year":"2022","unstructured":"Kim, S., Coukos, R., Gao, F. & Krainc, D. Dysregulation of organelle membrane contact sites in neurological diseases. Neuron 110, 2386\u20132408 (2022).","journal-title":"Neuron"},{"key":"999_CR160","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37454-4","volume":"14","author":"P Baden","year":"2023","unstructured":"Baden, P. et al. Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism. Nat. Commun. 14, 1930 (2023).","journal-title":"Nat. Commun."},{"key":"999_CR161","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41531-023-00616-8","volume":"9","author":"I Rosety","year":"2023","unstructured":"Rosety, I. et al. Impaired neuron differentiation in GBA-associated Parkinson\u2019s disease is linked to cell cycle defects in organoids. NPJ Parkinsons Dis. 9, 166 (2023).","journal-title":"NPJ Parkinsons Dis."},{"key":"999_CR162","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.tins.2021.12.004","volume":"45","author":"V Udayar","year":"2022","unstructured":"Udayar, V., Chen, Y., Sidransky, E. & Jagasia, R. Lysosomal dysfunction in neurodegeneration: emerging concepts and methods. Trends Neurosci. 45, 184\u2013199 (2022).","journal-title":"Trends Neurosci."},{"key":"999_CR163","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1126\/science.aan6298","volume":"358","author":"M Abu-Remaileh","year":"2017","unstructured":"Abu-Remaileh, M. et al. Lysosomal metabolomics reveals V-ATPase- and mTOR-dependent regulation of amino acid efflux from lysosomes. Science 358, 807\u2013813 (2017).","journal-title":"Science"},{"key":"999_CR164","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37632-4","volume":"14","author":"A Gehrlein","year":"2023","unstructured":"Gehrlein, A. et al. Targeting neuronal lysosomal dysfunction caused by \u03b2-glucocerebrosidase deficiency with an enzyme-based brain shuttle construct. Nat. Commun. 14, 2057 (2023).","journal-title":"Nat. Commun."},{"key":"999_CR165","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41582-020-0373-z","volume":"16","author":"M Kampmann","year":"2020","unstructured":"Kampmann, M. CRISPR-based functional genomics for neurological disease. Nat. Rev. Neurol. 16, 465\u2013480 (2020).","journal-title":"Nat. Rev. Neurol."},{"key":"999_CR166","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1038\/s41593-021-00862-0","volume":"24","author":"R Tian","year":"2021","unstructured":"Tian, R. et al. Genome-wide CRISPRi\/a screens in human neurons link lysosomal failure to ferroptosis. Nat. Neurosci. 24, 1020\u20131034 (2021).","journal-title":"Nat. Neurosci."},{"key":"999_CR167","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1002\/mds.29190","volume":"37","author":"Y Meng","year":"2022","unstructured":"Meng, Y. et al. Putaminal recombinant glucocerebrosidase delivery with magnetic resonance-guided focused ultrasound in Parkinson\u2019s disease: a phase I study. Mov. Disord. 37, 2134\u20132139 (2022).","journal-title":"Mov. Disord."},{"key":"999_CR168","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.1016\/j.cell.2021.08.002","volume":"184","author":"T Logan","year":"2021","unstructured":"Logan, T. et al. Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic. Cell 184, 4651\u20134668.e25 (2021).","journal-title":"Cell"},{"key":"999_CR169","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1474-4422(23)00205-3","volume":"22","author":"N Giladi","year":"2023","unstructured":"Giladi, N. et al. Safety and efficacy of venglustat in GBA1-associated Parkinson\u2019s disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 22, 661\u2013671 (2023).","journal-title":"Lancet Neurol."},{"key":"999_CR170","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/mds.27903","volume":"35","author":"E Sidransky","year":"2020","unstructured":"Sidransky, E. et al. Substrate reduction therapy for GBA1-associated Parkinsonism: are we betting on the wrong mouse? Mov. Disord. 35, 228\u2013230 (2020).","journal-title":"Mov. Disord."},{"key":"999_CR171","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1073\/pnas.1616152114","volume":"114","author":"SP Sardi","year":"2017","unstructured":"Sardi, S. P. et al. Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models. Proc. Natl Acad. Sci. USA 114, 2699\u20132704 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"999_CR172","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","volume":"77","author":"S Mullin","year":"2020","unstructured":"Mullin, S. et al. Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial. JAMA Neurol. 77, 427\u2013434 (2020).","journal-title":"JAMA Neurol."},{"key":"999_CR173","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2023-000535","volume":"5","author":"F Colucci","year":"2023","unstructured":"Colucci, F. et al. Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in GBA-associated Parkinson\u2019s disease: a multicentre, randomised, double-blind, placebo-controlled, phase II trial. The AMBITIOUS study protocol. BMJ Neurol. Open. 5, e000535 (2023).","journal-title":"BMJ Neurol. Open."},{"key":"999_CR174","doi-asserted-by":"publisher","first-page":"1163184","DOI":"10.3389\/fnagi.2023.1163184","volume":"15","author":"LJ Chwiszczuk","year":"2023","unstructured":"Chwiszczuk, L. J. et al. The ANeED study \u2013 ambroxol in new and early dementia with Lewy bodies (DLB): protocol for a phase IIa multicentre, randomised, double-blinded and placebo-controlled trial. Front. Aging Neurosci. 15, 1163184 (2023).","journal-title":"Front. Aging Neurosci."},{"key":"999_CR175","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1002\/mds.29346","volume":"38","author":"JM den Heijer","year":"2023","unstructured":"den Heijer, J. M. et al. A phase 1B trial in GBA1-associated Parkinson\u2019s disease of BIA-28-6156, a glucocerebrosidase activator. Mov. Disord. 38, 1197\u20131208 (2023).","journal-title":"Mov. Disord."},{"key":"999_CR176","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.1212\/WNL.0000000000201418","volume":"100","author":"L Oftedal","year":"2023","unstructured":"Oftedal, L. et al. Association of CSF glucocerebrosidase activity with the risk of incident dementia in patients with Parkinson disease. Neurology 100, e388\u2013e395 (2023).","journal-title":"Neurology"},{"key":"999_CR177","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13024-015-0010-2","volume":"10","author":"D Chiasserini","year":"2015","unstructured":"Chiasserini, D. et al. Selective loss of glucocerebrosidase activity in sporadic Parkinson\u2019s disease and dementia with Lewy bodies. Mol. Neurodegener. 10, 15 (2015).","journal-title":"Mol. Neurodegener."},{"key":"999_CR178","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.tins.2019.05.010","volume":"42","author":"T Farfel-Becker","year":"2019","unstructured":"Farfel-Becker, T., Do, J., Tayebi, N. & Sidransky, E. Can GBA1-associated Parkinson disease be modeled in the mouse? Trends Neurosci. 42, 631\u2013643 (2019).","journal-title":"Trends Neurosci."},{"key":"999_CR179","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/ana.22400","volume":"69","author":"V Cullen","year":"2011","unstructured":"Cullen, V. et al. Acid \u03b2-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter \u03b1-synuclein processing. Ann. Neurol. 69, 940\u2013953 (2011).","journal-title":"Ann. Neurol."},{"key":"999_CR180","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2210442120","volume":"120","author":"X Zhao","year":"2023","unstructured":"Zhao, X. et al. PGRN deficiency exacerbates, whereas a brain penetrant PGRN derivative protects, GBA1 mutation-associated pathologies and diseases. Proc. Natl Acad. Sci. USA 120, e2210442120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"999_CR181","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ymgme.2017.11.001","volume":"122","author":"N Tayebi","year":"2017","unstructured":"Tayebi, N. et al. Glucocerebrosidase haploinsufficiency in A53T \u03b1-synuclein mice impacts disease onset and course. Mol. Genet. Metab. 122, 198\u2013208 (2017).","journal-title":"Mol. Genet. Metab."},{"key":"999_CR182","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1523\/JNEUROSCI.0680-22.2022","volume":"43","author":"CL Mahoney-Crane","year":"2023","unstructured":"Mahoney-Crane, C. L. et al. Neuronopathic GBA1L444P mutation accelerates glucosylsphingosine levels and formation of hippocampal \u03b1-synuclein inclusions. J. Neurosci. 43, 501\u2013521 (2023).","journal-title":"J. Neurosci."},{"key":"999_CR183","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.neuron.2021.03.022","volume":"109","author":"DM Ramos","year":"2021","unstructured":"Ramos, D. M., Skarnes, W. C., Singleton, A. B., Cookson, M. R. & Ward, M. E. Tackling neurodegenerative diseases with genomic engineering: a new stem cell initiative from the NIH. Neuron 109, 1080\u20131083 (2021).","journal-title":"Neuron"},{"key":"999_CR184","doi-asserted-by":"publisher","first-page":"100261","DOI":"10.1016\/j.xgen.2023.100261","volume":"3","author":"E Bressan","year":"2023","unstructured":"Bressan, E. et al. The foundational data initiative for Parkinson disease: enabling efficient translation from genetic maps to mechanism. Cell Genom. 3, 100261 (2023).","journal-title":"Cell Genom."},{"key":"999_CR185","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2200553119","volume":"119","author":"MC Deen","year":"2022","unstructured":"Deen, M. C. et al. A versatile fluorescence-quenched substrate for quantitative measurement of glucocerebrosidase activity within live cells. Proc. Natl Acad. Sci. USA 119, e2200553119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"999_CR186","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202309306","volume":"62","author":"S Zhu","year":"2023","unstructured":"Zhu, S. et al. A fixable fluorescence-quenched substrate for quantitation of lysosomal glucocerebrosidase activity in both live and fixed cells. Angew. Chem. Int. Ed. Engl. 62, e202309306 (2023).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"999_CR187","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3233\/JPD-230295","volume":"14","author":"T Jong","year":"2024","unstructured":"Jong, T., Gehrlein, A., Sidransky, E., Jagasia, R. & Chen, Y. Characterization of novel human \u03b2-glucocerebrosidase antibodies for Parkinson\u2019s disease research. J. Parkinsons Dis. 14, 65\u201378 (2024).","journal-title":"J. Parkinsons Dis."},{"key":"999_CR188","doi-asserted-by":"publisher","first-page":"eadf8966","DOI":"10.1126\/sciadv.adf8966","volume":"9","author":"SG Scharenberg","year":"2023","unstructured":"Scharenberg, S. G. et al. An SPNS1-dependent lysosomal lipid transport pathway that enables cell survival under choline limitation. Sci. Adv. 9, eadf8966 (2023).","journal-title":"Sci. Adv."},{"key":"999_CR189","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1126\/science.adg9288","volume":"381","author":"UN Medoh","year":"2023","unstructured":"Medoh, U. N. et al. The Batten disease gene product CLN5 is the lysosomal bis(monoacylglycero)phosphate synthase. Science 381, 1182\u20131189 (2023).","journal-title":"Science"},{"key":"999_CR190","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.devcel.2020.11.016","volume":"56","author":"OB Davis","year":"2021","unstructured":"Davis, O. B. et al. NPC1-mTORC1 signaling couples cholesterol sensing to organelle homeostasis and is a targetable pathway in Niemann\u2013Pick type C. Dev. Cell. 56, 260\u2013276.e7 (2021).","journal-title":"Dev. Cell."},{"key":"999_CR191","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.neuron.2019.07.014","volume":"104","author":"R Tian","year":"2019","unstructured":"Tian, R. et al. CRISPR interference-based platform for multimodal genetic screens in human iPSC-derived neurons. Neuron 104, 239\u2013255.e12 (2019).","journal-title":"Neuron"},{"key":"999_CR192","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.cell.2014.09.029","volume":"159","author":"LA Gilbert","year":"2014","unstructured":"Gilbert, L. A. et al. Genome-scale CRISPR-mediated control of gene repression and activation. Cell 159, 647\u2013661 (2014).","journal-title":"Cell"},{"key":"999_CR193","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1093\/hmg\/ddw185","volume":"25","author":"J Magalhaes","year":"2016","unstructured":"Magalhaes, J. et al. Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease. Hum. Mol. Genet. 25, 3432\u20133445 (2016).","journal-title":"Hum. Mol. Genet."},{"key":"999_CR194","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1073\/pnas.1700465115","volume":"115","author":"S Kim","year":"2018","unstructured":"Kim, S. et al. GBA1 deficiency negatively affects physiological \u03b1-synuclein tetramers and related multimers. Proc. Natl Acad. Sci. USA 115, 798\u2013803 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"999_CR195","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1089\/ars.2015.6307","volume":"23","author":"EM Rocha","year":"2015","unstructured":"Rocha, E. M. et al. Sustained systemic glucocerebrosidase inhibition induces brain \u03b1-synuclein aggregation, microglia and complement C1q activation in mice. Antioxid. Redox Signal. 23, 550\u2013564 (2015).","journal-title":"Antioxid. Redox Signal."},{"key":"999_CR196","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.cmet.2013.04.014","volume":"17","author":"LD Osellame","year":"2013","unstructured":"Osellame, L. D. et al. Mitochondria and quality control defects in a mouse model of Gaucher disease \u2013 links to Parkinson\u2019s disease. Cell Metab. 17, 941\u2013953 (2013).","journal-title":"Cell Metab."},{"key":"999_CR197","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1172\/JCI117160","volume":"93","author":"WM Holleran","year":"1994","unstructured":"Holleran, W. M. et al. Consequences of \u03b2-glucocerebrosidase deficiency in epidermis. Ultrastructure and permeability barrier alterations in Gaucher disease. J. Clin. Invest. 93, 1756\u20131764 (1994).","journal-title":"J. Clin. Invest."},{"key":"999_CR198","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/s41586-022-05221-y","volume":"609","author":"NN Laqtom","year":"2022","unstructured":"Laqtom, N. N. et al. CLN3 is required for the clearance of glycerophosphodiesters from lysosomes. Nature 609, 1005\u20131011 (2022).","journal-title":"Nature"},{"key":"999_CR199","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1126\/science.aar2663","volume":"360","author":"GA Wyant","year":"2018","unstructured":"Wyant, G. A. et al. NUFIP1 is a ribosome receptor for starvation-induced ribophagy. Science 360, 751\u2013758 (2018).","journal-title":"Science"},{"key":"999_CR200","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33881-x","volume":"13","author":"H Park","year":"2022","unstructured":"Park, H. et al. Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics. Nat. Commun. 13, 6112 (2022).","journal-title":"Nat. Commun."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-00999-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-00999-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-00999-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T13:25:17Z","timestamp":1725283517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-00999-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":200,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["999"],"URL":"https:\/\/doi.org\/10.1038\/s41582-024-00999-z","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,6]]},"assertion":[{"value":"8 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}